Literature DB >> 25365589

Is sphere assay useful for the identification of cancer initiating cells of the ovary?

María José Martínez-Serrano1, Miguel Caballero-Baños, Ramon Vilella, Laura Vidal, Jaume Pahisa, Sergio Martínez-Roman.   

Abstract

OBJECTIVE: Current evidence suggests that the presence of tumor-initiating cells (TICs) in epithelial ovarian cancer (EOC) has a role in chemoresistance and relapse. Surface markers such as CD44(+)/CD24(-), CD117(+), and CD133(+) expression have been reported as potential markers for TICs related to ovarian cancer and tumorigenic cell lines. In this study, we have investigated if spheroid forms are TIC specific or whether they can also be produced by somatic stem cells from healthy tissue in vitro. In addition, we also investigated the specificity of surface markers to identify TICs from papillary serous EOC patients.
METHODS: Cells were obtained from fresh tumors from 10 chemotherapy-naive patients with EOC, and cells from ovarian and tubal epithelium were obtained from 5 healthy menopausal women undergoing surgery for benign pathology and cultured in standard and in selective medium. Cells forming nonadherent spheroids were considered TICs, and the adherent cells were considered as non-TIC-like. Percentages of CD24(+), CD44(+), CD117(+), CD133(+), and vascular endothelial growth factor receptor (VEGF-R)(+) cell surface markers were analyzed by flow cytometry.
RESULTS: Four of 10 EOC cell tissues were excluded from the study. Tumor cells cultured in selective medium developed spheroid forms after 1 to 7 weeks in 5 of 6 EOC patients. No spheroid forms were observed in cultures of cells from healthy women. Unlike previously published data, low levels of CD24(+), CD44(+), CD117(+), and VEGF-R(+) expression were observed in spheroid cells, whereas expression of CD133(+) was moderate but higher in adherent cells from papillary serous EOC cells in comparison with adherent cells from controls.
CONCLUSIONS: Papillary serous EOC contains TICs that form spheroids with low expression of CD44(+), CD24(+), CD117(+) and VEGF-R(+). Further research is required to find specific surface markers to identify papillary serous TICs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25365589     DOI: 10.1097/IGC.0000000000000320

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  An emerging question about putative cancer stem cells in established cell lines-are they true stem cells or a fluctuating cell phenotype?

Authors:  Pranesh Gunjal; Daniel Pedziwiatr; Ahmed A Ismail; Sham S Kakar; Mariusz Z Ratajczak
Journal:  J Cancer Stem Cell Res       Date:  2015-02-27

2.  B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models.

Authors:  Benjamin B Kasten; Rebecca C Arend; Ashwini A Katre; Harrison Kim; Jinda Fan; Soldano Ferrone; Kurt R Zinn; Donald J Buchsbaum
Journal:  Nucl Med Biol       Date:  2017-01-10       Impact factor: 2.408

3.  Novel population of small tumour-initiating stem cells in the ovaries of women with borderline ovarian cancer.

Authors:  Irma Virant-Klun; Martin Stimpfel
Journal:  Sci Rep       Date:  2016-10-05       Impact factor: 4.379

4.  Epigenetic Regulation of Claudin-1 in the Development of Ovarian Cancer Recurrence and Drug Resistance.

Authors:  Zachary R Visco; Gregory Sfakianos; Carole Grenier; Marie-Helene Boudreau; Sabrina Simpson; Isabel Rodriguez; Regina Whitaker; Derek Y Yao; Andrew Berchuck; Susan K Murphy; Zhiqing Huang
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

5.  Small putative NANOG, SOX2, and SSEA-4-positive stem cells resembling very small embryonic-like stem cells in sections of ovarian tissue in patients with ovarian cancer.

Authors:  Irma Virant-Klun; Natasa Kenda-Suster; Spela Smrkolj
Journal:  J Ovarian Res       Date:  2016-03-03       Impact factor: 4.234

6.  Elucidation of molecular and functional heterogeneity through differential expression network analyses of discrete tumor subsets.

Authors:  Rutika R Naik; Nilesh L Gardi; Sharmila A Bapat
Journal:  Sci Rep       Date:  2016-05-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.